GlycoMimetics announces plans to conduct public sale of common stock

Jefferies and Cowen are the bookrunners; deal funds clinical trials

By Devika Patel

Knoxville, Tenn., June 16 – GlycoMimetics, Inc. plans to price a public offering of common stock with a 30-day greenshoe, according to a preliminary prospectus supplement filed Thursday with the Securities and Exchange Commission.

Jefferies LLC and Cowen and Co., LLC are the bookrunners.

Proceeds will be used for clinical trials of GMI-1271, research and development, including drug discovery, working capital and other general corporate purposes.

The clinical stage biotechnology company is based in Gaithersburg, Md.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.